> ## Content Index
> Fetch the complete content index at: https://www.pennystocks.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# A Rare Eye Disease Gene Therapy Shows Vision Gains in Every Patient Treated
- URL: https://www.pennystocks.news/ird-a-rare-eye-disease-gene-therapy-shows-vision-gains-in-ev/
- Published: 2026-09-10T16:20:25.000Z
- Updated: 2026-09-10T16:20:25.000Z
- Description: Every patient in the first group improved, and no serious adverse events were recorded. The FDA has agreed on what a pivotal trial needs to show, and Phase 3 dosing is planned for 2027.
- Author: PennyStocksNews Team
- Tags: nasdaq, ticker-ird

Five patients enrolled in the first group of Opus Genetics' gene therapy trial for a rare inherited retinal disease. **All five showed clinically meaningful gains in visual function,** and none experienced a serious adverse event, the company said in a September 9 announcement.

Opus Genetics, Inc. NASDAQ: IRD 

The therapy, OPGx-BEST1, is delivered beneath the retina in a single procedure. It carries a working copy of the BEST1 gene to the retinal pigment epithelium — the cell layer that keeps photoreceptors alive. Mutations in BEST1 damage that layer progressively, causing vision loss. No approved treatment currently addresses the genetic root cause.

Three of the five patients improved on standard visual acuity testing. **Three of four evaluable patients showed better retinal sensitivity on microperimetry,** a test that maps how well the central retina detects light across a defined area. Structural improvements — including reductions in the abnormal deposits that define the most common form of the disease — appeared in four of the five. The company notes that the largest gains occurred in patients with less advanced disease, where viable retinal tissue remained.

**Shares closed 32.03% higher at $5.7300** after the announcement, on dollar volume of about $332 million.

The FDA's position, reached in a meeting last month, makes the clinical finding more consequential. The agency aligned with Opus Genetics on a potential endpoint for a confirmatory trial: a gain of **at least 3 decibels on microperimetry** across five pre-specified measurement points, combined with a patient-reported outcome, in a randomised controlled design. The company says it expects to complete Phase 3 manufacturing requirements in early 2027 and to begin participant dosing that year.

Ahead of that, the company has advanced to a higher-dose second group. **Eight patients enrolled** — three more than originally planned — and dosing is expected to wrap up in the fourth quarter of 2026, with three-month results due in the second quarter of 2027.

New epidemiology research commissioned by the company estimates roughly **23,600 symptomatic BEST1 patients in the US** — including both diagnosed and undiagnosed cases — and about 45,400 worldwide, figures the company says are substantially larger than earlier estimates. Cash on hand is expected to cover operations into 2029, the company says, long enough to reach multiple clinical milestones.

Higher-dose Cohort 2 results and the start of Phase 3 enrolment are both expected in the same quarter.